Canaccord Genuity Reiterates a 'Buy' on Integrated Device Technology (IDTI); Servers Driving Better-than-Seasonal Trends
IDTI Hot Sheet
Rating Summary:1 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 82
Canaccord Genuity reiterates a 'Buy' on Integrated Device Technology (NASDAQ: IDTI) price target raised to $8.00.
Analyst, Bobby Burleson, said, "We reiterate a Buy on shares of IDTI and increase our price target following largely in-line results (soft revenues, EPS upside) and slightly soft guidance. Management sees Romley server upgrade driving better-than-seasonal revenues for Computing in the March quarter. We believe upside to our revised estimates could come from server memory interface and wireless infrastructure over the next few quarters."
For an analyst ratings summary and ratings history on Integrated Device Technology click here. For more ratings news on Integrated Device Technology click here.
Shares of Integrated Device Technology closed at $6.64 yesterday, with a 52 week range of $4.70-$8.74.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
Analyst, Bobby Burleson, said, "We reiterate a Buy on shares of IDTI and increase our price target following largely in-line results (soft revenues, EPS upside) and slightly soft guidance. Management sees Romley server upgrade driving better-than-seasonal revenues for Computing in the March quarter. We believe upside to our revised estimates could come from server memory interface and wireless infrastructure over the next few quarters."
For an analyst ratings summary and ratings history on Integrated Device Technology click here. For more ratings news on Integrated Device Technology click here.
Shares of Integrated Device Technology closed at $6.64 yesterday, with a 52 week range of $4.70-$8.74.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Barclays maintains an 'Equalweight' on Tech Data (TECD); Slight Adjustments on Q1 Results
- Nomura Securities Maintains a 'Neutral' on Urban Outfitters (URBN); Staying Sidelined Despite Positive Q1 Surprises
- Canaccord Genuity maintains a 'Buy' on Auxilium Pharmaceuticals (AUXL); Bumping Guidance on Testim Partnership with GSK
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Genuity Capital MarketsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
